The partial shutdown of the US FDA that began Dec. 21 seems destined to continue at least a while longer, leaving sponsors unable to file applications and the agency unable to conduct inspections, among other stoppages.
The so-called "lapse period" (the second in 2018) began after Congress failed to pass an appropriations bill for FDA and...








